<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707625</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00064405</org_study_id>
    <nct_id>NCT04707625</nct_id>
  </id_info>
  <brief_title>Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment</brief_title>
  <official_title>Correlation of Vascular Endothelial Growth Factor Levels in Anterior Chamber Fluid to Disease State in Patients With Retinal Vein Occlusion Receiving Standard of Care Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to treat patients with retinal vein occlusion with standard of&#xD;
      care anti-vascular endothelial growth factor therapy and to correlate levels of vascular&#xD;
      endothelial growth factor in the anterior chamber fluid of the eye. This study will evaluate&#xD;
      if measuring the vascular endothelial growth factor will help predict the timing of when&#xD;
      anti-vascular endothelial growth factor therapy will be needed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ten patients, 5 with branch retinal vein occlusion and 5 with central retinal vein occlusion,&#xD;
      will receive stand of care anti-vascular endothelial growth factor over the course of 52&#xD;
      weeks while undergoing a paracentesis prior to each treatment. During the paracentesis&#xD;
      anterior chamber fluid will be removed to evaluate vascular endothelial growth factor levels&#xD;
      along with other cytokines present in the anterior chamber fluid. Ocular coherence tomography&#xD;
      will also be collected at each visit to evaluate macular thickness which will be used to help&#xD;
      determine treatment windows along with levels of vascular endothelial growth factor. Patients&#xD;
      with high levels of vascular endothelial growth factor and the presence of macular edema on&#xD;
      ocular coherence tomography will be treated every four weeks. Once vascular endothelial&#xD;
      growth factor levels are reduced along with improvements of macula edema treatment windows&#xD;
      will be extended to 8 weeks and then to 12 weeks once levels are normal and edema is no&#xD;
      longer present.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients will receive the same standard of care treatment.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Macular Edema</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Measured by central retinal thickness using optical coherence tomography - OCT is an imaging method used to generate a picture of the back of the eye, called the retina. The picture is made by precisely measuring the amount of a dim red light that reflects off the retina</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Macular Volume</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Measured by central retinal thickness using optical coherence tomography - OCT is an imaging method used to generate a picture of the back of the eye, called the retina. The picture is made by precisely measuring the amount of a dim red light that reflects off the retina</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Vascular Endothelial Growth Factor (VEGF) level in Anterior Chamber</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Evaluated by Enzyme-Linked ImmunoSorbent Assay (ELISA) analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Using Snellen Visual Acuity charts - The results are based on what line the patient can read with ease - If a subject's visual acuity is so poor that the subject can't see any letters on the charts, finger counting and/or hand motions will be checked</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Intraocular Pressure (IOP)</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Evaluated by tonometry - Tonometry is the procedure eye care professionals perform to determine the intraocular pressure (IOP), the fluid pressure inside the eye - Most tonometers are calibrated to measure pressure in millimeters of mercury (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Intravitreal Injections</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Number of injections received during study participation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Analytes - Chemokine (C-C motif) ligand (CCL)s</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Chemokine (C-C motif) ligand 2 (CCL2)/(JE/MCP-1) Monocyte chemoattractant protein 1 and C-C motif chemokine 11(CCL11)/Eotaxin - Analyzed using an ELISA multiplex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Analytes - chemokine (C-X-C motif) ligand (CXCL)s</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>CXCL1/GRO alpha/KC/Cytokine-induced neutrophil chemoattractant (CINC-1) and CXCL2/GRO beta/MIP-s/CINC-3 - Analyzed using an ELISA multiplex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Analytes - Growth factors</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Epidermal growth factor (EGF) and basic fibroblast growth factor (FGF basic)/FGF2/bFGF - and Transforming growth factor alpha (TGF-alpha) - and Platelet-derived growth factor (PDGF)-AA and PDGF-AB/BBA analyzed using an ELISA multiplex Analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Analytes - Interferons</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Interferon (IFN)-alpha 2/IFNA2, Interferon (IFN)-beta, and Interferon (IFN)-gamma - Analyzed using an ELISA multiplex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Analytes - Interleukins</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>IL-1 alpha/IL-1F1&#xD;
IL-1 beta/IL-1F2&#xD;
IL-1ra/IL-1F3&#xD;
IL-2&#xD;
IL-3&#xD;
IL-4&#xD;
IL-5&#xD;
IL-6&#xD;
IL-7&#xD;
IL-8/CXCL8&#xD;
IL-10&#xD;
IL-12 p70&#xD;
IL-13&#xD;
IL-15&#xD;
IL-17/IL-17A&#xD;
IL-17E/IL-25&#xD;
IL-33 Analyzed using an ELISA multiplex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Analytes - Proteins</measure>
    <time_frame>Baseline through week 52</time_frame>
    <description>Programmed death-ligand 1(PD-L1)/B7 homolog 1(B7-H1) Analyzed using an ELISA multiplex</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects will receive aflibercept every 4 weeks. Once vascular endothelial growth factor levels become normal and macular edema improves treatment windows will be extended up to every 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept Ophthalmic</intervention_name>
    <description>Anti-vascular endothelial growth factor intraocular injection</description>
    <arm_group_label>Aflibercept</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willingness and ability to provide written informed consent.&#xD;
&#xD;
          -  Diagnosis of Retinal Vein Occlusion with macular edema and central foveal thickness of&#xD;
             greater than or equal to 300 microns confirmed by intravenous fluorescein angiography&#xD;
             and Optical Coherence Tomography&#xD;
&#xD;
          -  Visual Acuity between 20/25 and 5/200&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bilateral Retinal Vein Occlusion&#xD;
&#xD;
          -  Vision worse than 5/200 in study eye&#xD;
&#xD;
          -  History of myocardial infarction, ischemia, or cerebrovascular accident within 6 weeks&#xD;
             of screening&#xD;
&#xD;
          -  Concurrent Proliferative Diabetic Retinopathy and/or Maculopathy&#xD;
&#xD;
          -  Concurrent Exudative Age-related Macular Degeneration&#xD;
&#xD;
          -  Concurrent optic neuropathy with the presence of an afferent pupillary defect&#xD;
&#xD;
          -  Previous vitrectomy in the study eye&#xD;
&#xD;
          -  Currently pregnant or planning to become pregnant during the duration of the study.&#xD;
             Women currently breastfeeding are also excluded.&#xD;
&#xD;
          -  Previous treatment for retinal vein occlusion in the study eye&#xD;
&#xD;
          -  Any current medical condition which, in the opinion of the investigator is considered&#xD;
             to be uncontrolled&#xD;
&#xD;
          -  History of allergy or hypersensitivity to study treatment, fluorescein, or any study&#xD;
             procedure and treatment related ingredients (e.g. topical anesthetics, betadine, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Nelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest Baptist Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Nelson, MD</last_name>
    <phone>336-713-1680</phone>
    <email>mhnelson@wakehealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Blair Gordy</last_name>
    <phone>336-716-3937</phone>
    <email>bgordy@wakehealth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wake Forest Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mark Nelson, MD</last_name>
      <phone>336-716-3937</phone>
      <email>mhnelson@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Blair Gordy</last_name>
      <phone>336-716-3937</phone>
      <email>bgordy@wakehealth.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.regeneron.com/sites/default/files/EYLEA_FPI.pdf</url>
    <description>Eyla prescribing information</description>
  </link>
  <reference>
    <citation>Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology. 2016 Feb;123(2):330-336. doi: 10.1016/j.ophtha.2015.09.035. Epub 2015 Oct 30.</citation>
    <PMID>26522708</PMID>
  </reference>
  <reference>
    <citation>Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol. 2014 Nov;158(5):1032-8. doi: 10.1016/j.ajo.2014.07.027. Epub 2014 Jul 25.</citation>
    <PMID>25068637</PMID>
  </reference>
  <reference>
    <citation>Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014 Jul;121(7):1414-1420.e1. doi: 10.1016/j.ophtha.2014.01.027. Epub 2014 Mar 27. Erratum in: Ophthalmology. 2014 Nov;121(11):2293.</citation>
    <PMID>24679444</PMID>
  </reference>
  <reference>
    <citation>Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013 Jul;27(7):787-94. doi: 10.1038/eye.2013.107. Epub 2013 May 31. Review.</citation>
    <PMID>23722722</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vision Loss</keyword>
  <keyword>Eye Injections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD at this time.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

